Inactive Instrument

Idogen AB (publ)

Equities

IDOGEN

SE0014428561

Biotechnology & Medical Research

Idogen AB Reports Earnings Results for the Third Quarter Ended September 30, 2020

October 23, 2020 at 02:47 am EDT

Idogen AB (publ) announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was SEK 6.747 million compared to SEK 6.753 million a year ago. Net loss was SEK 4.729 million compared to SEK 6.622 million a year ago. For the nine months, operating loss was SEK 24.868 million compared to SEK 24.822 million a year ago. Net loss was SEK 18.925 million compared to SEK 24.487 million a year ago.

Latest news about Idogen AB (publ)

Certain Shares of Idogen AB are subject to a Lock-Up Agreement Ending on 12-JUL-2023.	23-07-11	CI
Idogen Delisted from Nasdaq First North Growth Market Amid Bankruptcy	23-07-10	MT
Cell Therapy Group Idogen Formally Files for Bankruptcy After Merger Talks Fail	23-07-07	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	23-05-30	MT
Idogen Mulls Sale of Proprietary Technology Platform Amid Looming Liquidation	23-05-30	MT
Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Idogen Discusses Reverse Takeover with Several Parties	23-04-28	CI
Idogen to Propose Liquidation at June Annual Meeting, Kicks Off Reverse Merger Talks	23-04-28	MT
Sweden's Idogen Warns of Liquidation if Capital Plan Fails; Shares Plunge 35%	23-04-18	MT
Idogen AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
Idogen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Idogen AB Appoints Jan Holgersson to Its Board of Directors	22-11-21	CI
Idogen Chair Steps Down, Former Chairman To Take Up Role Again	22-11-02	MT
Idogen AB Announces Board Changes	22-11-01	CI
Sweden's Idogen Bags Last Tranche of EU Grant for Hemophilia Drug Study	22-10-17	MT
Idogen AB Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program	22-10-13	CI
Idogen AB Sharpens Focus on its IDO 8 Program and Lowers Operating Expenditure	22-10-03	CI
Idogen AB to Commence the Phase I/IIa Clinical Trial of its Drug Candidate in the IDO 8 Program	22-10-03	CI
Idogen AB Announces Board Changes	22-09-27	CI
Idogen Wins Approval For Hemophilia Medication Study At Oslo University Hospital In Norway	22-09-21	MT
Idogen Receives Approval from the Regional Ethics Committee to Conduct Clinical Phase I/IIa Study	22-09-21	CI
Idogen Appoints Christina Herder as Acting CEO	22-09-13	CI
Redeye Updates Their Analysis of Idogen as Company Approaches Clinical Phase	22-09-05	CI

Chart Idogen AB (publ)

Duration

Period

More charts

Company Profile

Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The Company is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs